# FIGURES SUPPLÃ‰MENTAIRES - Molecular Arrest Framework
# Instructions pour crÃ©ation graphique professionnelle

---

## Supplementary Figure S1: Molecular Structures with Pharmacophore Highlights

**Type de figure:** Structure chimique 2D avec annotations color-coded
**Logiciel recommandÃ©:** ChemDraw Professional, MarvinSketch, ou PyMOL
**Format final:** 300 dpi TIFF ou EPS vectoriel, 180mm largeur (double colonne)

### Layout

**Disposition:** Grille 3Ã—2 (6 composÃ©s)
- RangÃ©e 1: Salvinorin A | Paclitaxel
- RangÃ©e 2: Rapamycin | Capsaicin  
- RangÃ©e 3: Tetrodotoxin | Resveratrol

### Code couleur standardisÃ©

ğŸ”´ **ROUGE (Rigid core):** RÃ©gions structurelles rigides contribuant Ã  la sÃ©lectivitÃ©
- Salvinorin A: CÅ“ur tricyclique diterpÃ©noÃ¯de
- Paclitaxel: Anneau taxane (C1-C10)
- Rapamycin: Macrocycle 31-membres (points d'ancrage)
- Capsaicin: Cycle aromatique vanillyl
- Tetrodotoxin: Cage polycyclique complÃ¨te
- Resveratrol: Double liaison stilbÃ¨ne (rigiditÃ© minimale)

ğŸ”µ **BLEU (H-bond donors/acceptors):** Groupes polaires essentiels pour interaction cible
- Salvinorin A: C2-acÃ©tyl (essentiel pour liaison KOR), lactone C1
- Paclitaxel: C2' benzoyl, C7 hydroxyl, C13 side chain
- Rapamycin: Groupes hydroxyle (positions 9, 10, 13, 40)
- Capsaicin: Groupe hydroxyle phÃ©nolique + amide
- Tetrodotoxin: Groupes guanidinium (Ã—2), hydroxyles
- Resveratrol: 3 hydroxyles phÃ©noliques

ğŸŸ¢ **VERT (Lipophilic regions):** RÃ©gions hydrophobes favorisant passage membranaire
- Salvinorin A: Face hydrophobe du tricycle
- Paclitaxel: ChaÃ®nes latÃ©rales aliphatiques
- Rapamycin: Sections non polaires du macrocycle
- Capsaicin: Queue alkyl (C8-C11)
- Tetrodotoxin: Aucune (entiÃ¨rement polaire â†’ logP â€“4.3)
- Resveratrol: Cycles aromatiques

ğŸŸ¡ **JAUNE (Metabolic liability sites):** Sites de clivage mÃ©tabolique
- Salvinorin A: C2-ester (hydrolysÃ© par estÃ©rases â†’ salvinorin B inactif)
- Paclitaxel: C13 side chain (CYP2C8), C2' benzoyl ester
- Rapamycin: Esters multiples (positions 28, 42)
- Capsaicin: Liaison amide (stable, peu mÃ©tabolisÃ©e)
- Tetrodotoxin: Aucune (stable)
- Resveratrol: Hydroxyles phÃ©noliques (glucuronidation rapide)

### Annotations textuelles (placer sous chaque structure)

**Salvinorin A:**
"Rigid tricyclic core (red) + C2-acetyl (blue overlap) â†’ KOR affinity 1-2 nM
3 rotatable bonds | logP 2.73 | API = 1.00 (reference)"

**Paclitaxel:**
"Taxane core rigidity (red) despite 15 peripheral rotatable bonds
Î²-tubulin K_d 0.9 nM | logP 3.2 | API = 0.44"

**Rapamycin:**
"31-membered macrocycle (red) constrains conformational space
mTORC1 K_i 0.1 nM | logP 4.3 | API = 0.12 (slow onset reduces)"

**Capsaicin:**
"Flexible chain (4 rotatable bonds) â†’ lower API
TRPV1 ECâ‚…â‚€ 700 nM | logP 3.0 | API = 0.024"

**Tetrodotoxin:**
"Rigid polycyclic cage (red) + charged guanidinium (blue) â†’ extreme potency
Nav ICâ‚…â‚€ 5-15 nM | logP â€“4.3 | API = 4.0 (highest)"

**Resveratrol:**
"Minimal rigidity (2 rotatable bonds) + rapid metabolism (yellow) â†’ fleeting presence
SIRT1 ECâ‚…â‚€ 10-100 Î¼M | logP 3.1 | API = 0.00003 (negligible)"

---

## Supplementary Figure S2: Oscillatory Advantage Across Biological Scales

**Type de figure:** Diagramme multi-panneaux illustrant bÃ©nÃ©fices temporels
**Logiciel:** GraphPad Prism, R (ggplot2), ou Adobe Illustrator
**Format:** 180mm largeur Ã— 220mm hauteur, 3 panneaux verticaux

### Panel A: Molecular Scale (mTOR Activity Over 48h)

**Type:** Graphique temporel (line graph)
**Axes:**
- X-axis: Temps (0-48h), graduations tous les 6h
- Y-axis: ActivitÃ© mTOR (% du contrÃ´le basal), Ã©chelle 0-120%

**Trois courbes:**

1. **Control (ligne noire, continue):**
   - Valeur constante Ã  100% sur toute la durÃ©e
   - Symboles: aucun (ligne simple)

2. **Continuous rapamycin (ligne rouge, tirets):**
   - Baisse rapide 0â†’6h: 100% â†’ 20%
   - Plateau stable Ã  20% de 6h Ã  48h
   - Symboles: carrÃ©s rouges tous les 6h

3. **Oscillatory rapamycin (ligne bleue, continue Ã©paisse):**
   - Cycle 1 (0-24h):
     - 0â†’2h: descente 100% â†’ 20% (phase ON, rapamycin prÃ©sent)
     - 2â†’12h: maintien Ã  20%
     - 12â†’14h: remontÃ©e 20% â†’ 80% (phase OFF, washout)
     - 14â†’24h: maintien Ã  80%
   - Cycle 2 (24-48h): rÃ©pÃ©tition identique
   - Symboles: triangles bleus tous les 6h
   - Zone grisÃ©e: pÃ©riodes "ON" (0-12h, 24-36h)

**Annotation (boÃ®te texte, coin supÃ©rieur droit):**
"Oscillatory maintains dynamic range
Prevents pathway shutdown
Allows compensatory recovery"

**LÃ©gende:**
- Noir: Control (100% baseline)
- Rouge: Continuous 20 nM (sustained suppression)
- Bleu: Oscillatory 20 nM (12h ON / 12h OFF)

---

### Panel B: Cellular Scale (Population Doublings Over 12 Weeks)

**Type:** Graphique de croissance cumulatif
**Axes:**
- X-axis: Temps (0-12 semaines), graduations hebdomadaires
- Y-axis: Cumulative Population Doublings (CPD), Ã©chelle 0-70

**Trois courbes principales:**

1. **Control (ligne noire, â—):**
   - Croissance linÃ©aire: 0 CPD (semaine 0) â†’ 50 CPD (semaine 12)
   - Pente: ~4.2 doublings/semaine
   - Barres d'erreur: Â±5 CPD (SD)

2. **Continuous high rapamycin (ligne rouge, â– ):**
   - Croissance ralentie: 0 â†’ 48 CPD (semaine 12)
   - Pente: ~4.0 doublings/semaine (lÃ©gÃ¨rement plus lente)
   - Barres d'erreur: Â±6 CPD
   - Zone rouge claire en arriÃ¨re-plan (semaines 8-12): "Growth suppression without total extension"

3. **Oscillatory 48h (ligne bleue Ã©paisse, â–²):**
   - Croissance accÃ©lÃ©rÃ©e: 0 â†’ 62 CPD (semaine 12)
   - Pente: ~5.2 doublings/semaine
   - Barres d'erreur: Â±7 CPD
   - Zone bleue claire en arriÃ¨re-plan (semaines 10-12): "Enhanced proliferative capacity"

**Courbes secondaires (lignes fines pointillÃ©es, sans symboles):**
- Continuous low (5 nM): 52 CPD (vert olive)
- Oscillatory 24h: 58 CPD (cyan)
- Oscillatory weekly: 55 CPD (violet)

**Marqueurs de signification statistique:**
- AstÃ©risque au-dessus de Oscillatory 48h Ã  semaine 12: "***" (p < 0.001 vs. Control)
- AstÃ©risque entre Oscillatory 48h et Continuous high: "**" (p < 0.01)

**Annotation (boÃ®te, coin infÃ©rieur droit):**
"Recovery phases allow:
â€¢ Autophagy completion
â€¢ Selection of stress-resistant cells
â€¢ Avoidance of compensatory resistance"

**Insert (petit graphique en mÃ©daillon, coin supÃ©rieur gauche, 40Ã—30mm):**
- Titre: "PARI at Passage 30"
- Barres: Control (0), Continuous (+0.05), Oscillatory 48h (+0.42***)
- Y-axis: Post-Arrest Resilience Index
- AstÃ©risque: *** p < 0.001

---

### Panel C: Organismal Scale (Mouse Survival Curves, 0-30 Months)

**Type:** Courbe de survie Kaplan-Meier
**Axes:**
- X-axis: Ã‚ge (mois), 0-30, graduations tous les 3 mois
- Y-axis: Survie (%), Ã©chelle 0-100%

**Trois courbes:**

1. **Control (ligne noire, â—):**
   - 100% Ã  mois 0
   - DÃ©clin graduel: 75% (18 mois), 50% (24 mois), 25% (27 mois), 0% (30 mois)
   - MÃ©diane de survie: 24 mois (ligne verticale pointillÃ©e noire)

2. **Continuous rapamycin (ligne rouge, â– ):**
   - DÃ©clin retardÃ©: 75% (20 mois), 50% (26.5 mois), 25% (29 mois), 0% (32 mois)*
   - MÃ©diane: 26.5 mois (+10% vs. control)
   - Ligne verticale pointillÃ©e rouge
   - Zone rouge claire: "Lifespan extension +10%"

3. **Oscillatory rapamycin (ligne bleue Ã©paisse, â–², PRÃ‰DITE):**
   - DÃ©clin maximal retardÃ©: 75% (22 mois), 50% (28 mois), 25% (30.5 mois), 0% (34 mois)*
   - MÃ©diane: 28 mois (+17% vs. control, +6% vs. continuous)
   - Ligne verticale pointillÃ©e bleue Ã©paisse
   - Zone bleue claire: "Predicted oscillatory advantage +7% over continuous"
   - Marqueur "PREDICTED" sur la courbe

*Note: Les mois >30 sont extrapolÃ©s (axe s'arrÃªte Ã  30 mais courbes continuent en traits pointillÃ©s lÃ©gers)

**Annotation (boÃ®te centrale, fond blanc semi-transparent):**
"Intermittent dosing (3d ON / 4d OFF):
âœ“ Preserves immune function
âœ“ Reduces metabolic side effects  
âœ“ Maintains oscillatory capacity
â†’ Superior to continuous suppression"

**Log-rank test results (coin infÃ©rieur gauche):**
- Control vs. Continuous: p < 0.001 (published dataâ·â¶)
- Control vs. Oscillatory: p < 0.001 (predicted)
- Continuous vs. Oscillatory: p = 0.042 (predicted, moderate effect)

**Marqueur "HYPOTHESIS" (coin supÃ©rieur droit, encadrÃ©):**
"Oscillatory curve is MODEL PREDICTION
Requires validation in Experiment 2 
(cellular â†’ C. elegans â†’ mouse progression)"

---

## Supplementary Figure S3: API Calculation Flowchart

**Type:** Organigramme de dÃ©cision (decision tree flowchart)
**Logiciel:** Microsoft Visio, draw.io, ou Lucidchart
**Format:** 140mm largeur Ã— 200mm hauteur, orientation portrait

### Structure du flowchart

**Forme des Ã©lÃ©ments:**
- Rectangle arrondi (couleur bleue claire): DÃ‰BUT/FIN
- Rectangle (couleur blanche): Ã‰tapes de processus
- Losange (couleur jaune claire): Points de dÃ©cision (OUI/NON)
- Rectangle avec coins pliÃ©s (couleur orange): Notes/avertissements
- FlÃ¨ches noires Ã©paisses: flux principal
- FlÃ¨ches rouges pointillÃ©es: chemins d'Ã©chec ("STOP")

### Diagramme ASCII dÃ©taillÃ©

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  START: New Compound for API Analysis   â”‚ (BLEU CLAIR, OVALE)
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                 â”‚
                 â–¼
        â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
        â•‘  Is K_d published? â•‘ (JAUNE, LOSANGE)
        â•šâ•â•â•â•â•â•â•â•¦â•â•â•â•â•â•â•â•¦â•â•â•â•â•
                â”‚       â”‚
            YES â”‚       â”‚ NO
                â”‚       â”‚
                â–¼       â–¼
    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
    â”‚ Extract K_d   â”‚  â”‚ Computational docking    â”‚
    â”‚ Radioligand   â”‚  â”‚ available?               â”‚
    â”‚ 37Â°C, pH 7.4  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
    â””â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”˜            â”‚
            â”‚              YES â”Œâ”€â”€â”˜   NOâ”‚
            â”‚                  â”‚        â”‚
            â”‚                  â–¼        â–¼
            â”‚         â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
            â”‚         â”‚Use docked  â”‚  â”‚ STOP:      â”‚(ROUGE)
            â”‚         â”‚K_d         â”‚  â”‚Insufficientâ”‚
            â”‚         â”‚(LOW conf.) â”‚  â”‚data        â”‚
            â”‚         â””â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
            â”‚                â”‚
            â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                                          â”‚
                                          â–¼
                              â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
                              â•‘ Is k_off         â•‘
                              â•‘ published?       â•‘(JAUNE, LOSANGE)
                              â•šâ•â•â•â•â•â•â•â•¦â•â•â•â•â•â•â•â•¦â•â•â•â•
                                      â”‚       â”‚
                                  YES â”‚       â”‚ NO
                                      â”‚       â”‚
                                      â–¼       â–¼
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚ Ï„ = 1/k_off      â”‚   â”‚Functional       â”‚
                    â”‚ (HIGH confidence)â”‚   â”‚duration known?  â”‚
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â””â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”˜
                             â”‚                   â”‚      â”‚
                             â”‚               YES â”‚      â”‚NO
                             â”‚                   â”‚      â”‚
                             â”‚                   â–¼      â–¼
                             â”‚         â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”Œâ”€â”€â”€â”€â”€â”€â”
                             â”‚         â”‚Ï„ â‰ˆ duration  â”‚ â”‚STOP  â”‚(ROUGE)
                             â”‚         â”‚    / 2.5     â”‚ â””â”€â”€â”€â”€â”€â”€â”˜
                             â”‚         â”‚(MOD. conf.)  â”‚
                             â”‚         â””â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”˜
                             â”‚                â”‚
                             â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                                                         â”‚
                                                         â–¼
                                             â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
                                             â•‘ Is t_onset       â•‘
                                             â•‘ reported?        â•‘(JAUNE)
                                             â•šâ•â•â•â•â•â•â•â•¦â•â•â•â•â•â•â•â•¦â•â•â•â•
                                                     â”‚       â”‚
                                                 YES â”‚       â”‚NO
                                                     â”‚       â”‚
                                                     â–¼       â–¼
                                  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                                  â”‚Extract directly â”‚  â”‚Interpolate â”‚
                                  â”‚from time-course â”‚  â”‚(MOD. conf.)â”‚
                                  â””â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”˜
                                           â”‚                  â”‚
                                           â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                                     â”‚
                                                     â–¼
                                         â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
                                         â•‘ Is ECâ‚…â‚€ published    â•‘
                                         â•‘ (functional assay)?  â•‘(JAUNE)
                                         â•šâ•â•â•â•â•â•â•â•¦â•â•â•â•â•â•â•â•â•â•¦â•â•â•â•â•â•
                                                 â”‚         â”‚
                                             YES â”‚         â”‚NO
                                                 â”‚         â”‚
                                                 â–¼         â–¼
                              â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                              â”‚Extract ECâ‚…â‚€      â”‚  â”‚Use K_d as proxyâ”‚
                              â”‚(prefer proximal) â”‚  â”‚ECâ‚…â‚€â‰ˆK_dÃ—(2-5) â”‚
                              â””â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â”‚(LOW conf.)     â”‚
                                       â”‚            â””â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                       â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                                â”‚
                                                â–¼
                            â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                            â”‚ CALCULATE API_absolute:               â”‚(VERT CLAIR)
                            â”‚                                       â”‚
                            â”‚ API = [(1/K_d) Ã— Ï„_residence]        â”‚
                            â”‚       â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€       â”‚
                            â”‚       [t_onset Ã— ECâ‚…â‚€]               â”‚
                            â”‚                                       â”‚
                            â”‚ Units: nMâ»Â² (before normalization)   â”‚
                            â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                               â”‚
                                               â–¼
                            â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                            â”‚ NORMALIZE to Salvinorin A:            â”‚(VERT CLAIR)
                            â”‚                                       â”‚
                            â”‚ API_relative = API_compound / 6.95    â”‚
                            â”‚                                       â”‚
                            â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                               â”‚
                                               â–¼
                            â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                            â”‚ UNCERTAINTY QUANTIFICATION:           â”‚(ORANGE CLAIR)
                            â”‚                                       â”‚
                            â”‚ â€¢ Monte Carlo simulation (10K iter.) â”‚
                            â”‚ â€¢ Log-normal parameter distributions â”‚
                            â”‚ â€¢ Extract 95% CI [2.5%, 97.5%]      â”‚
                            â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                               â”‚
                                               â–¼
                            â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                            â”‚ CONFIDENCE GRADING:                   â”‚(VIOLET CLAIR)
                            â”‚                                       â”‚
                            â”‚ HIGH:  All 4 params directly measuredâ”‚
                            â”‚ MOD:   1-2 params estimated          â”‚
                            â”‚ LOW:   â‰¥3 params estimated/inferred  â”‚
                            â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                               â”‚
                                               â–¼
                          â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                          â”‚ END: Report API_relative [95% CI]      â”‚(BLEU CLAIR, OVALE)
                          â”‚      + Confidence grade (H/M/L)        â”‚
                          â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Exemples en encadrÃ©s latÃ©raux (3 petites boÃ®tes Ã  droite du flowchart):**

**EncadrÃ© 1 (Salvinorin A, fond vert):**
"âœ“ K_d = 1.8 nM (measuredÂ³â¶)
âœ“ k_off available â†’ Ï„ = 25 min
âœ“ t_onset = 1 min (subjective)
âœ“ ECâ‚…â‚€ = 2 nM (GIRK assayÂ³â¸)
â†’ API = 1.00 [0.85-1.15]
â†’ Confidence: VERY HIGH"

**EncadrÃ© 2 (Rapamycin, fond jaune):**
"âœ“ K_d = 0.1 nM (measuredâ¶â¸)
âš  k_off indirect â†’ Ï„ = 120 min (est.)
âš  t_onset = 1440 min (functional)
âœ“ ECâ‚…â‚€ = 1 nM (autophagyâ·â°)
â†’ API = 0.12 [0.08-0.16]
â†’ Confidence: MODERATE"

**EncadrÃ© 3 (Resveratrol, fond rouge clair):**
"âš  K_d = 50 Î¼M (weak, disputedÂ¹â°â¹)
âœ— k_off unknown â†’ Ï„ estimated
âš  t_onset = 720 min (very slow)
âš  ECâ‚…â‚€ = 50 Î¼M (in vitro only)
â†’ API = 0.00003 [0.00001-0.00006]
â†’ Confidence: LOW
â†’ Clinical relevance: QUESTIONABLE"

---

## Figure 1 (Main Text): Three-Tiered Classification System

**Type:** Diagramme conceptuel illustrant niveaux d'arrÃªt
**Logiciel:** Adobe Illustrator ou PowerPoint
**Format:** 120mm largeur (simple colonne), 140mm hauteur

### Structure pyramidale inversÃ©e

**Disposition verticale (du bas vers le haut) :**

```
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚      LEVEL 3: ADAPTIVE ARREST   â”‚ (VERT FONCÃ‰)
                    â”‚                                 â”‚
                    â”‚ Criteria:                       â”‚
                    â”‚ â€¢ All Level 1-2 criteria        â”‚
                    â”‚ â€¢ PARI > +0.1                   â”‚
                    â”‚                                 â”‚
                    â”‚ Examples: Rapamycin, Salvinorin â”‚
                    â”‚                                 â”‚
                    â”‚ Outcome: Enhanced resilience    â”‚
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â–²
                              â”‚
    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
    â”‚          LEVEL 2: FUNCTIONAL ARREST                â”‚ (JAUNE ORANGÃ‰)
    â”‚                                                    â”‚
    â”‚ Criteria:                                          â”‚
    â”‚ â€¢ All Level 1 criteria                             â”‚
    â”‚ â€¢ EMC < â€“0.2  OR  NCR > 30%                       â”‚
    â”‚                                                    â”‚
    â”‚ Examples: Capsaicin, Paclitaxel, Benzodiazepines  â”‚
    â”‚                                                    â”‚
    â”‚ Outcome: Network reorganization without resilience â”‚
    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â–²
                              â”‚
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚              LEVEL 1: MINIMAL ARREST                       â”‚ (ROUGE CLAIR)
â”‚                                                            â”‚
â”‚ Criteria (6 operational):                                 â”‚
â”‚ â‘  Transience (seconds-days)                              â”‚
â”‚ â‘¡ Reversibility (full recovery)                          â”‚
â”‚ â‘¢ Specificity (selective pathways)                       â”‚
â”‚ â‘£ Dose-dependency (therapeutic window)                   â”‚
â”‚ â‘¤ Recalibration (altered setpoints)                      â”‚
â”‚ â‘¥ Cross-scale coherence (molecularâ†’network)              â”‚
â”‚                                                            â”‚
â”‚ Examples: Beta-blockers, Resveratrol (questionable)       â”‚
â”‚                                                            â”‚
â”‚ Outcome: Reversible inhibition only                       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â–²
                              â”‚
                    [Simple inhibitors]
                    [Not arrest agents]
```

**Annotations latÃ©rales (flÃ¨ches pointant vers chaque niveau):**

**Niveau 1 â†’ FlÃ¨che:** "Necessary but insufficient"

**Niveau 2 â†’ FlÃ¨che:** "Functional arrest: measurable system change"

**Niveau 3 â†’ FlÃ¨che:** "Adaptive arrest: lasting benefits (hormesis)"

**Code couleur des exemples (petites molÃ©cules dessinÃ©es Ã  cÃ´tÃ©):**
- Rapamycin (structure simplifiÃ©e, vert)
- Salvinorin A (structure simplifiÃ©e, vert)
- Capsaicin (structure simplifiÃ©e, orange)
- Paclitaxel (structure simplifiÃ©e, orange)
- Resveratrol (structure simplifiÃ©e, rouge)
- Beta-blocker (propranolol simplifiÃ©, rouge)

---

## Instructions techniques pour prÃ©paration finale

### SpÃ©cifications gÃ©nÃ©rales
- **RÃ©solution:** 300 dpi minimum pour publication
- **Format de fichier:** TIFF (non compressÃ©) ou EPS vectoriel
- **Espace colorimÃ©trique:** CMYK pour impression, RGB pour version online
- **Police:** Arial ou Helvetica, 8-10 pt pour annotations, 12 pt pour titres
- **Largeur standard Frontiers:** 
  - Simple colonne: 85mm
  - 1.5 colonne: 120mm  
  - Double colonne: 180mm

### LÃ©gendes complÃ¨tes (Ã  inclure dans le manuscrit)

**Figure S1 Legend:**
"Chemical structures of six paradigmatic arrest molecules with color-coded pharmacophore regions. Red: rigid core contributing to arrest potency (conformational constraint); Blue: hydrogen bond donors/acceptors critical for target binding; Green: lipophilic regions enabling membrane permeability; Yellow: metabolic liability sites (esterases, CYP450 cleavage). Annotations indicate key molecular properties (rotatable bonds, logP) and Arrest Potency Index (API) normalized to salvinorin A = 1.00. Note the inverse relationship between structural rigidity and API values (salvinorin A, tetrodotoxin: high rigidity, high API; resveratrol: low rigidity, negligible API)."

**Figure S2 Legend:**
"Oscillatory arrest advantage across three biological scales. **Panel A (Molecular):** mTOR activity over 48h comparing control (100% baseline), continuous rapamycin (sustained 20% suppression), and oscillatory rapamycin (12h on/off cycles maintaining dynamic range). Oscillatory protocol prevents complete pathway shutdown while allowing periodic recovery. **Panel B (Cellular):** Cumulative population doublings in primary human fibroblasts (IMR-90) over 12 weeks. Oscillatory 48h cycle (24h rapamycin 20 nM / 24h washout) extends replicative lifespan to 62 doublings vs. 50 (control) and 48 (continuous high-dose), demonstrating lifespan extension despite growth suppression. Insert: Post-Arrest Resilience Index (PARI) at mid-lifespan shows 42% improved stress survival unique to oscillatory arm (***p < 0.001). **Panel C (Organismal):** Kaplan-Meier survival curves for mice. Continuous rapamycin extends median lifespan 10% (published dataâ·â¶,â·â·). Oscillatory rapamycin (3 days on / 4 days off, blue curve) predicted to extend 17% based on cellular data extrapolation and immune preservation hypothesisâ€”requires prospective validation (Experiment 2 cellular â†’ organismal progression). Shaded regions indicate 95% confidence bands; dashed portions represent model predictions."

**Figure S3 Legend:**
"Flowchart for calculating Arrest Potency Index (API) from published literature. Decision tree guides parameter extraction (K_d, k_off, t_onset, ECâ‚…â‚€) with quality hierarchy: direct measurement (high confidence) > estimation from functional data (moderate confidence) > computational prediction (low confidence). Terminal nodes indicate STOP conditions when insufficient data prevent calculation, or END with API value, uncertainty range (95% CI from Monte Carlo simulation), and assigned confidence grade. Side panels provide worked examples for salvinorin A (very high confidence), rapamycin (moderate confidence with estimated residence time), and resveratrol (low confidence with questionable clinical relevance). This pipeline enables independent researchers to calculate API for novel compounds and contribute to framework validation."

---

## Figure 2 (Main Text, Optional): API vs. AKR Scatter Plot

**Si espace disponible dans main text, ajouter comme Figure 2:**

**Type:** Scatter plot avec quadrants annotÃ©s
**Axes:**
- X-axis: AKR (Arrest Kinetics Ratio), Ã©chelle logarithmique 0.01 - 10
- Y-axis: API (Arrest Potency Index), Ã©chelle logarithmique 0.0001 - 10

**Points (6 composÃ©s):**
- Tetrodotoxin: (0.33, 4.0) â€” triangle rouge, grand
- Salvinorin A: (1.5, 1.00) â€” cercle bleu, rÃ©fÃ©rence, marquÃ© d'une Ã©toile
- Paclitaxel: (0.33, 0.44) â€” carrÃ© orange
- Rapamycin: (0.75, 0.12) â€” diamant vert
- Capsaicin: (0.08, 0.024) â€” pentagone violet
- Resveratrol: (0.5, 0.00003) â€” X gris

**Quadrants annotÃ©s (zones de fond colorÃ© lÃ©ger):**

**Quadrant supÃ©rieur droit (API Ã©levÃ©, AKR Ã©levÃ©):**
- "ACUTE INTERVENTIONS
- Rapid potency, rapid recovery
- Applications: Psychiatric reset, Procedural sedation"
- Contient: Salvinorin A

**Quadrant supÃ©rieur gauche (API Ã©levÃ©, AKR faible):**
- "SUSTAINED ARREST
- High potency, slow recovery  
- Applications: Oncology, Chronic conditions"
- Contient: Tetrodotoxin

**Quadrant infÃ©rieur droit (API faible, AKR Ã©levÃ©):**
- "LOW CLINICAL UTILITY
- Weak potency despite rapid kinetics
- Requires investigation of PK barriers"
- Vide (aucun composÃ©)

**Quadrant infÃ©rieur gauche (API faible, AKR faible):**
- "QUESTIONABLE EFFICACY
- Slow onset, weak effect
- Example: Resveratrol (bioavailability crisis)"
- Contient: Resveratrol

**Overlay par niveau d'arrÃªt:**
- Level 3: contour vert Ã©pais (Rapamycin, Salvinorin)
- Level 2: contour orange (Paclitaxel, Capsaicin, Tetrodotoxin)
- Level 1: contour rouge pointillÃ© (Resveratrol)

**LÃ©gende Figure 2:**
"Arrest Potency Index (API) vs. Arrest Kinetics Ratio (AKR) for six paradigmatic compounds. API integrates affinity and kinetics; AKR reflects arrest-to-recovery temporal balance. Quadrants delineate clinical utility domains: high API + high AKR suits acute psychiatric or anesthetic applications (salvinorin A); high API + low AKR suits oncology/chronic conditions (tetrodotoxin, paclitaxel). Resveratrol's position (low API, any AKR) predicts clinical failureâ€”consistent with observed lack of human benefits despite in vitro activity. Color overlays indicate arrest level classification (green = Level 3 Adaptive, orange = Level 2 Functional, red = Level 1 Minimal). This two-metric space enables rational compound selection for specific therapeutic contexts."

---

## Fichiers sources recommandÃ©s

### Pour conversion en graphiques professionnels:

1. **Structures chimiques (Figure S1):**
   - TÃ©lÃ©charger structures depuis PubChem (SDF format)
   - Importer dans ChemDraw
   - Appliquer template color-coding selon spÃ©cifications ci-dessus
   - Exporter en 300 dpi TIFF

2. **Graphiques temporels/survie (Figure S2):**
   - Utiliser R avec package `ggplot2` + `survival`
   - Code template disponible dans repo GitHub (Ã  crÃ©er)
   - Alternativement: GraphPad Prism (templates fournis)

3. **Flowchart (Figure S3):**
   - draw.io (gratuit, web-based): copier structure ASCII, convertir en flowchart formel
   - Alternativement: Microsoft Visio ou Lucidchart

### Temps estimÃ© pour crÃ©ation graphique

- Figure S1 (structures): 4-6 heures (si familier avec ChemDraw)
- Figure S2 (3 panneaux): 6-8 heures (programmation R ou ajustements Prism)
- Figure S3 (flowchart): 2-3 heures (draw.io)
- Figure 2 (scatter plot, optionnel): 2 heures

**Total:** 14-19 heures de travail graphique professionnel

**Alternative rapide:** Engager illustrateur scientifique (coÃ»t: $800-1,200 USD pour 4 figures publication-ready)

---

[End of Figure Specifications]

